www.barrons.com
Open in
urlscan Pro
2600:9000:21f3:7e00:14:c68f:c40:93a1
Public Scan
URL:
https://www.barrons.com/articles/biotech-stock-meiragtx-51634331594
Submission: On October 21 via api from US — Scanned from DE
Submission: On October 21 via api from US — Scanned from DE
Form analysis 1 forms found in the DOM
<form autocomplete="off">
<div id="scrim-from-wrap" class="input-wrap">
<label for="scrim-from">From</label>
<textarea id="scrim-from" readonly="readonly" disabled="disabled" type="text" autocomplete="off" autocorrect="off" autocapitalize="none"></textarea>
</div>
<div id="scrim-to-wrap" class="input-wrap">
<label for="scrim-to">To</label>
<input id="scrim-to" type="text" autocomplete="off" autocorrect="off" autocapitalize="none">
</div>
<div class="input-wrap">
<label for="scrim-message">Message</label>
<textarea id="scrim-message" class="msg" maxlength="500" type="text" autocomplete="off" autocorrect="off" autocapitalize="none"></textarea>
</div>
</form>Text Content
We've detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. CHROME SAFARI FIREFOX We've detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser.GoogleFirefox Search News & Quotes Barron's TopicsMagazineDataAdvisorPenta100 Years Subscribe Now |Sign In Barrons This Small Biotech Is Partnering With Johnson & Johnson. The Stock Could More Than Double. Next: Ford Is Solving the ‘Two Clock Problem’. It’s Great for the Stock. * * * * Share This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barrons.com/articles/biotech-stock-meiragtx-51634331594 * Biotech and Pharma * Sizing Up Small-Caps THIS SMALL BIOTECH IS PARTNERING WITH JOHNSON & JOHNSON. THE STOCK COULD MORE THAN DOUBLE. * * * * -------------------------------------------------------------------------------- By Bill Alpert Updated Oct. 16, 2021 10:54 am ET / Original Oct. 15, 2021 8:00 pm ET * Order Reprints * Print Article Illustration by Kyle Ellingson Since the excitement of multibillion-dollar acquisitions of gene-therapy firms by Novartis and Roche Holding a few years ago, many gene-therapy stocks have sunk to small-cap valuations. Among them is MeiraGTx Holdings, shares of which fell from a 2019 peak of $30 to a recent $14, leaving its market capitalization below $600 million—and only a half-dozen analysts paying it heed. That’s an opportunity for investors. MeiraGTx (ticker: MGTX) has several treatments in clinical trials, some of the industry’s best manufacturing centers,... Subscribe or Sign In to continue reading -------------------------------------------------------------------------------- * Autos * Street Notes FORD IS SOLVING THE ‘TWO CLOCK PROBLEM’. IT’S GREAT FOR THE STOCK. * * * * -------------------------------------------------------------------------------- By Al Root Oct. 20, 2021 10:21 am ET * Order Reprints * Print Article Wall Street is getting more bullish on Ford Motor stock as the company works on improving both its near-term and long-term results. Wednesday, Credit Suisse analyst Dan Levy upgraded shares of Ford (ticker: F) to Buy from Hold. His target for the stock price went to $20 from $15. Shares were at $15.64 early on Wednesday. According to the... Subscribe or Sign In to continue reading -------------------------------------------------------------------------------- More from News Corp * Realtor.com Looking to buy your first home? You’ve come to the right place. * PENTA Residential Real Estate Returns to Earth, but Will Remain Strong * Realtor.com Front Door Color Meanings: Your Front Door Color Reveals More About You Than You'd Think * Financial News London Deutsche bolsters UK investment bank with two senior dealmakers * Wall Street Journal Children’s Books: ‘Ferryman’ Review Close THIS SMALL BIOTECH IS PARTNERING WITH JOHNSON & JOHNSON. THE STOCK COULD MORE THAN DOUBLE. Since the excitement of multibillion-dollar acquisitions of gene-therapy firms by Novartis and Roche Holding a few years ago, many gene-therapy stocks have sunk to small-cap valuations. From To Message SEND An error has occurred, please try again later. Thank you This article has been sent to Privacy Notice Cookie Notice Do Not Sell My Personal Information Copyright Policy Data Policy Your Ad Choices Subscriber Agreement & Terms of Use Barron's Archive Corporate Subscriptions Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. Barron's Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.